Project
A retrospective, Swiss multi-center study to investigate the efficacy of natalizumab in second line therapy
Completed ยท 2008 until 2009
Putzki Norman
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed
Start Date
2008
End Date
2009
Financing
Self Financed
Study Design
retrospective, non-controlled
Keywords
multiple sclerosis, natalizumab, treatment failure
Partner
Biogen Idec
Additional Information
submitted to European Neurology
Brief description/objective
Natalizumab is restricted to patients with treatment failure to IFN-beta and to highly active MS. The pivotal trials were not designed to examine this scenario. This study seeks to add at least 100 patient years experience in second line therapy of RRMS.